{"ticker": {"uuid": "f6f0f4bb-36d0-4f62-9ce6-3448de0bbb97", "symbol": "RIGL", "name": "Rigel Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOemZXOUdmbjBTSElVX3dRYTlGckNCelc3VFhSY0gwOTVmbGlZeU9wb1BaaXRHRDNoSlNxdVNZXzV5Z0dxX1hBdUpXdGV2cG1paTFsOFB4RTEyelJ1SUoxVGVRQjlZOGFfYzNLQ2FOYkgybWdKcElRWmdHM1l1QWNpbk5yYUJIblBEdmdRY1c2N0ZtMFBTWTFaOG9iN0VYUXVUMVZURHduRXJjV2xOVVI5Nng4MmpfOWN1amt5WFBpb0RNOXI4Mkg4bw?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-06T07:58:22+00:00", "published_display": "06 Aug 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57", "summary": "H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US), maintaining a target price of $57. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/74156453/hc-wainwright-maintains-rigel-pharmaceuticals-riglus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-08-06T08:41:24", "published_display": "06 Aug 2026 08:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts", "summary": "Rigel Pharmaceuticals (RIGL) saw its stock rally after its Q2 earnings release, with a 4.6% increase following a strong three-month run. The company maintained profitability with $17.3m in net income and $78.7m in total revenue, though revenue and EPS declined significantly year-", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rigl/rigel-pharmaceuticals/news/rigel-pharmaceuticals-rigl-stock-rally-runs-into-earnings-qu/amp", "source_name": "Simply Wall Street", "published_at": "2026-08-06T08:41:24", "published_display": "06 Aug 2026 08:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPanQ1a3hmdEs0Q3JoOTZUT3NsUEVLWHY5QjZhZUdPZkNVWEN5Qy1LUnJCby1PR2ZDRWVWOVRob1ZlZy1QVGhMWi1TRmdldFQxOFlCTV9ucHNKWnVEd1ZteDBEUlA0R191dkVlcFlXRm1WT21EN3RqWmhIc2VCYV9RNm5lMW1lbVZpcnZDUVlpQ29iUl8yX1JmaXhMR2FuVm1ON25wRWZ2dUh0T2c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-08-06T02:10:28+00:00", "published_display": "06 Aug 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNLVhkcWQzM0puSUx1ZS1qcWxwOE9RcUx5a1dRb3lQcXFpNG8ydEs4b2J2b2o3Q3hvT0tvczFOQU1OTlFYb0I4QXdTNFlnekJ5eXd5cnF4RjFIaTBCYWRzVjZ2VWNJcW9uR3A1eWxQNHI1MDBidUY3bnpJaVUwS2hfcEFTM0QzVVlQZnFEWEFzLUQtY1VDejJhNzB4ZWNKdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-08-05T18:29:23+00:00", "published_display": "05 Aug 2026 18:29", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/27667a71-d85c-3d85-88ee-3565f4d6ad27/rigel-pharmaceuticals%2C-inc..html", "source_name": "Moby", "published_at": "2026-08-05T12:30:00+00:00", "published_display": "05 Aug 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. (RIGL) Latest Stock News & Headlines", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE9FLXV4eHRya1ZjQjRRc1JSdHRDbmotQWRIQ3p1b194TFNsNGF4bmFVQklQdjR4WGdoOUl2QUJFZ3JkNFRXTjVBRFVfUTZfQmRUZGxUVi1rWXg?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-08-05T04:51:34+00:00", "published_display": "05 Aug 2026 04:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals (RIGL) Overvalued After Q2 Earnings Bea", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOMUk5N194LXZPQXEwR2dta2RFZlV5azdrYWJ1LTZWWVBUd0xGQ0ZkTlJ2VVpsSWVQcFlyZ2xRTjdCTmNDbjZUdV9rS0JsVUNYc0VPSHFOUlR6YWg2Z0d5LWU2Q2Q1ZEtuOS1oc0lYUXFSYjl6S2gwWmZUU3BNdGNMaGpvbHVtSU11MGZEaFFzZnFKUDhWY3pWQVplRE9xRmFGUWVpZXRfOGhtX1VISVRJZlMxOHNrUDdveWNaNXZxcHdPeEhXbFhfZUtEbS1vRlRKNlVHQzlNM0lkRWIxVVpaSUpVcnBYQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-08-05T03:12:31+00:00", "published_display": "05 Aug 2026 03:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Q2 2026 Earnings Call Transcript", "summary": "Rigel Pharmaceuticals reported strong Q2 2026 results, with commercial revenue growing 14% year-over-year, driven by record TAVALISSE sales and REZLIDHIA growth. The company is accelerating the launch of VEPPANU, an FDA-approved breast cancer therapy, which it expects to be its l", "url": "https://www.marketbeat.com/earnings/reports/2026-8-4-rigel-pharmaceuticals-inc-stock/", "source_name": "MarketBeat", "published_at": "2026-08-05T03:11:56", "published_display": "05 Aug 2026 03:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Q2 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/601d4af5-8d35-3458-a9aa-2c976afe24d8/rigel-pharmaceuticals-q2.html", "source_name": "MarketBeat", "published_at": "2026-08-05T02:03:51+00:00", "published_display": "05 Aug 2026 02:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RIGL)", "summary": "Rigel Pharmaceuticals, Inc. (RIGL) published a slide deck in conjunction with their Q2 2026 earnings call. The company reported an EPS of $0.88, beating estimates by $0.96, and revenue of $78.70M, which also beat estimates by $23.43M despite a 22.60% year-over-year decrease. This", "url": "https://seekingalpha.com/article/4930435-rigel-pharmaceuticals-inc-2026-q2-results-earnings-call-presentation", "source_name": "Seeking Alpha", "published_at": "2026-08-05T02:43:19", "published_display": "05 Aug 2026 02:43", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates", "summary": "Rigel Pharmaceuticals (RIGL) reported Q2 earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share, and significantly down from $3.28 per share a year ago. Despite missing EPS estimates, the company's Q2 revenues of $78.7 million surpassed the consensus", "url": "https://finance.yahoo.com/healthcare/articles/rigel-pharmaceuticals-rigl-q2-earnings-211503917.html", "source_name": "Market source", "published_at": "2026-08-04T21:11:56", "published_display": "04 Aug 2026 21:11", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel: Q2 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rigel-q2-earnings-snapshot-200854036.html", "source_name": "Associated Press", "published_at": "2026-08-04T20:08:54+00:00", "published_display": "04 Aug 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Reports Second Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQWnYtcHFHQnVoTXFmUHp5OUtqbW9FUU5hY3dNZXZHa3p4VWxjNWRONlVtcEkwSS1xS2E1cFN3LXp3OUEtT1lDaVl6eC1SSFV6ckUzVWV5Qzl5eU9uRWJkSkZqdWgzdVZsR0Fic3ZjZjZPQ1FTSXBXTjUyMFJIZjZIaEpBMzdib0ZjbFZUOXpvNDBmR1lNU3JZeC04MlhpUGo4TlA2WFBQYWFwTWlSSlZURjhn?oc=5", "source_name": "TradingView", "published_at": "2026-08-04T20:01:00+00:00", "published_display": "04 Aug 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(RIGL) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models, highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies an exceptional short setup with a significant risk-reward ratio and outlines specific trading strategies f", "url": "https://news.stocktradersdaily.com/news_release/34/RIGL_as_a_Liquidity_Pulse_for_Institutional_Tactics_080426064202_1785883322.html", "source_name": "Stock Traders Daily", "published_at": "2026-08-04T19:11:56", "published_display": "04 Aug 2026 19:11", "sentiment": "negative", "sentiment_pct": 27, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Rigel Pharmaceuticals Inc (RIGL), noting its current risk score of 4.47 and ranking it 86th out of 155 in the Pharmaceuticals industry. It highlights the company's beta of 1.19, indicating higher volatility compared to the S&P 500 index", "url": "https://www.tradingkey.com/markets/stocks/rigl/risk-assesment", "source_name": "TradingKey", "published_at": "2026-07-30T05:39:37", "published_display": "30 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results", "summary": "Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to di", "url": "https://www.tradingview.com/news/prnewswire:e86e3e35e2be2:0-rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financial-results/", "source_name": "TradingView", "published_at": "2026-07-29T05:10:49", "published_display": "29 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Rigel Pharmaceuticals Inc (RIGL), highlighting its current valuation score and P/E ratio. It notes that the company's P/E ratio is 1.90, significantly below its recent high and above its recent low. The analysis also indicates that re", "url": "https://www.tradingkey.com/markets/stocks/rigl/company-valuation", "source_name": "TradingKey", "published_at": "2026-07-29T03:41:07", "published_display": "29 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel schedules a live webcast for its Aug. 4 business update", "summary": "Rigel Pharmaceuticals (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. A live conference call and webcast will follow at 4:30 p.m. ET, led by senior management, to discuss the results and provide a b", "url": "https://www.stocktitan.net/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-kmaj6q3vc7qu.html", "source_name": "Stock Titan", "published_at": "2026-07-28T12:11:44", "published_display": "28 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGL|Rigel Pharmaceuticals Inc|Price:37.126|Chg%:-0.264", "summary": "This article provides a comprehensive stock analysis of Rigel Pharmaceuticals Inc (RIGL) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways recently. The analysis also covers the company's valuation, instit", "url": "https://www.tradingkey.com/markets/stocks/rigl/stock-analysis", "source_name": "TradingKey", "published_at": "2026-07-28T03:39:19", "published_display": "28 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Rigel Pharmaceuticals Inc (RIGL), highlighting major institutional investors and their holdings. It breaks down shareholders by type and reports on changes in institutional ownership over several quarters. The data provides insigh", "url": "https://www.tradingkey.com/markets/stocks/rigl/ownership", "source_name": "TradingKey", "published_at": "2026-07-27T19:11:44", "published_display": "27 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Revenue Breakdown \u2013 NASDAQ:RIGL", "summary": "Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) generated $294.28 million in revenue last year, primarily from its Novel Therapies segment. This is an increase from $179.28 million the previous year. The United States was the company's largest contributor to revenue.", "url": "https://www.tradingview.com/symbols/NASDAQ-RIGL/financials-segments/", "source_name": "TradingView", "published_at": "2026-07-27T15:11:44", "published_display": "27 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Rigel Pharmaceuticals Inc (RIGL). It indicates that the company has not distributed any dividends in the past five years. The report also details multiple merger-related stock splits with a 10:1 ratio that oc", "url": "https://www.tradingkey.com/markets/stocks/rigl/dividend-splits", "source_name": "TradingKey", "published_at": "2026-07-27T02:09:49", "published_display": "27 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Income Statement", "summary": "This article provides the quarterly and annual income statements for Rigel Pharmaceuticals Inc (RIGL), offering detailed financial data such as total revenue, cost of revenue, operating expenses, and net income across multiple fiscal years and quarters. It also includes frequentl", "url": "https://www.tradingkey.com/markets/stocks/rigl/income-statement", "source_name": "TradingKey", "published_at": "2026-07-26T04:20:13", "published_display": "26 Jul 2026 04:20", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Revenue Breakdown \u2013 MUN:RI2", "summary": "Rigel Pharmaceuticals, Inc. (MUN:RI2) generated 250.56 million EUR last year, a significant increase from 173.18 million EUR in the previous year. This revenue primarily stemmed from its Novel Therapies segment, with the United States being the largest contributing region. The co", "url": "https://www.tradingview.com/symbols/MUN-RI2/financials-segments/", "source_name": "TradingView", "published_at": "2026-07-25T08:12:42", "published_display": "25 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Rigel Pharmaceuticals Inc (RIGL) has a robust financial health score of 8.03, ranking 86th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a 10.28% year-over-year revenue increase to $58.82 million and a 24.39% year-over-year", "url": "https://www.tradingkey.com/markets/stocks/rigl/financial-health", "source_name": "TradingKey", "published_at": "2026-07-24T14:40:15", "published_display": "24 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGEL PHARMACEUTICALS INC (RIGL) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5vUnBwNzkyVHBZUDJpNXZtcmdBSEZVQklJNUQ5NzlaWEUwQkg5SDJkQ2FRcElINjhBRjlCU2REWDRsX0s4SWF2R3g4ODNLdjNGTTRYZ3hZcUh1MUExNVpHR0JHXzA?oc=5", "source_name": "ChartMill", "published_at": "2026-07-23T17:27:27+00:00", "published_display": "23 Jul 2026 17:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(RIGL) Risk Channels and Responsive Allocation", "summary": "Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is presenting a weak near-term sentiment, although an exceptional 81.5:1 risk-reward setup is noted, targeting a 24.2% gain against 0.3% risk. AI models have developed three trading strategies: Position Trading (LONG), Momentum Breakout (", "url": "https://news.stocktradersdaily.com/news_release/39/RIGL_Risk_Channels_and_Responsive_Allocation_072326025401_1784832841.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-23T14:27:19", "published_display": "23 Jul 2026 14:27", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxPTFlzc3AzYmlzdG0zQXQ4eEd2TDJlT0h5bGlMVUdRd0JjLWd2Qm5kVU5oR3VWX19BVENjbXlqcVM3NFMwT0FDTHQwY05WNk96aGhpM3pQMWZWcExyeGVZaXFkeDVtMTlwVnM5RlNaTTNHYVhVYkFDQ3kwczlFeTlUN1huR1FJbHdBT2ZTajJ6VEFPVFI0MkZoMzRIMjc2Y182WEJpREFjZno4VzRDZF85R1lrdjNhVi1pYm01RHJDRTJmWHF0OHpMOXFyLTJuLWgydEFBX3JGTGtBSzlVSmdER2NnVUdJbERJVkRxOGo1MFlHMHZXMUxZU0hFOWxIdw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-12T07:00:00+00:00", "published_display": "12 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rigel Pharmaceuticals (RIGL) Q1 2026 earnings summary", "summary": "Rigel Pharmaceuticals (RIGL) announced total revenues of $58.8 million in Q1 2026, including $54.9 million in net product sales, marking a 26% year-over-year increase. The company maintained profitability with an $8.7 million net income despite higher R&D and SG&A expenses, drive", "url": "https://quartr.com/events/rigel-pharmaceuticals-inc-rigl-q1-2026_onMowkE1", "source_name": "Quartr", "published_at": "2026-07-11T11:10:56", "published_display": "11 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Corporate presentation Summary", "summary": "Rigel Pharmaceuticals' corporate presentation outlines its transformational growth strategy, focusing on expanding its commercial business, advancing its pipeline, and in-licensing. The company has grown from one commercial product in 2020 to three by 2025, with a fourth, VEPPANU", "url": "https://quartr.com/events/rigel-pharmaceuticals-inc-rigl-corporate-presentation_onMowpQs", "source_name": "Quartr", "published_at": "2026-07-11T11:10:56", "published_display": "11 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing by Rigel Pharmaceuticals Inc. for transactions that occurred on July 10th. The filing is a standard regulatory disclosure related to insider trading, though the article does not provide specific details from the form itself. The document si", "url": "https://ng.investing.com/news/stock-market-news/form-4-rigel-pharmaceuticals-inc-for-10-july-93CH-2595754", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T01:41:22", "published_display": "11 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) CMO receives 24,400-share RSU equity award with 4-year vesting", "summary": "Rigel Pharmaceuticals' EVP and Chief Medical Officer, Alison L. Hannah, was granted 24,400 Restricted Stock Units (RSUs) which will vest annually over four years, starting July 8, 2027. Following this award and the cancellation of 5,750 RSUs, Ms. Hannah directly holds 35,025 shar", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-8d44c3c9628b.html", "source_name": "Stock Titan", "published_at": "2026-07-11T01:40:25", "published_display": "11 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Proxy filing Summary", "summary": "Rigel Pharmaceuticals has issued a proxy filing summarized on April 3, 2026, outlining key proposals for its annual meeting scheduled for May 14, 2026. Shareholders will vote on the election of three directors, amendments to two equity incentive plans to add shares, an advisory v", "url": "https://quartr.com/events/rigel-pharmaceuticals-inc-rigl-proxy-filing_onMowMMR", "source_name": "Quartr", "published_at": "2026-07-08T08:39:51", "published_display": "08 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Announces Inducem", "summary": "NULL", "url": "https://www.moomoo.com/news/flash/22754760/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule", "source_name": "Moomoo", "published_at": "2026-07-07T20:11:01", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQUWJEdU5GS0FXZ1ZlYmRPd0cyVHZ1bEYwZHNEekVPRTAtaTJjYVVKbndNSnJGRFloUFFwU2ZlWk5GQ2pySjNNS2w5UXN6OW1YVFlGeWx3Y1ByWFVwNHFVeVlkZnE0TGZraUFHNm9EQkFQcGZaSS1FZWpNUXpSd2FLeGpsdm05ZGlzUE5lRjVZZFRhSGRzREZ1dXhQSkpHa2lBSnpDTTcyV0ZXSUN0eC1weUZYVjd0SzZsV0VSdGNhSDlYTnZyRTNrclVjbmtaSFpTTmVRYS12RlZZUQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (RIGL) director sells 2,500 shares under 10b5-1 plan for tax withholding", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNeWVjYnlwbVR4ZlAzTGpyOFNPWlhLUWFFVGtrOVZyX0FqOEJIRndMY0I4VlhNT2pqeDZpLTlPRjJZdlVWOG1WNXlwRkM0WExMbVl3QjhPTE52YW8wRkZLWUtOamhaMklla1RxdXliU2xvU19iQWRJcmlTSmxQU1NkMDBTSk5WaXQ3TVVSekVNdE14bDJVZUlLTHRwTjV3VUhFTDZNVWV4TkhOc3FMZ1JSbmRLRmFiMnZobmUw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) CEO gets 31,700 performance-based options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMEd2eXAtUFZUcHpQZFpZYnlOMDh5NUhBVWxVcjNtOE0wWFl1ZzJ3SV9IR04xeThCV1NETUNPa1VtWU1NclNUMGtBNWlMLVFYNDZ6N1RZa1djOTYwTWw4QzN1UHFKRHBxd1RsX1VPNnR3TjJKOGpwUE5FV3N4YzA4T2UyREVwY2FKV2lFN3dFbnV0YXUySk5WXzRxaF9iR3dvZ0ZtcFJ6NXM5SWFhMmhOSFZkdzdjYlYxVlFj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (RIGL) CFO\u2019s 7,394-share performance-based stock option fully vests", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOTA4aWpsYk9CMGFLYnBmbF8tLXNSNmotRW9qS3h2QmFfSGhwZExIblV5Z0hpeWxOcUdDNXNZZ0dsOU15dXdDa2I1RWpDbndYeTFtQy1zTXdNY3VZcXFjQzB4TWpjcEdYT2loZlBfRElEaW5Cd2NrNGQ2bDM0QWUyLUtpd0hKYW5PdjVvLWpERFl3SGRLRFVNLXZ3Z1NDenVqeC0waEVfM0xwYzBkbTBTX0tlS2p2YTBERlpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQaUl0VEFNeThOTThJcVFkTXM3VW9TYzVnNTVDakwxcTN2N0Z0aTl3clZqd1VYVlJfbmdTTjlBcjFJRkpRbElSdXhnWUtPZ3JrTGZ1UTBPM2ozOVdyMU9UanpMU1ZIOWRoa1VObnYtT0tZMjRGTkJIMGdGZzZ0NnVKekRrMFlZbi1LeGpxTWFSRF8zNDlHMEI0S2JB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA\u2011Approved Breast Cancer Drug VEPPANU", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Believe Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are A Poor Guide For Its Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSlg0NUxGb0FWRGZDd1lWWVBfVTI2dGpodU1aWElzQmtoaDBZaGduV2kxcEhuU0lxNHRSNjk0M3hhYWxiM2FRSjd1dGlGaHhoRUw0TVJRS1I5MTBNdGJCSVdvV3RycWFoTDlDZDFzdUJJbnVsWkJuWHhxWldlQno1QlpiZXZGU0Qtc3VDTXBMQkduRGNFTk4tVzBzRVpnalRJeFNzQkg1QXREQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQaGV1U0l6X0FFczVfTkR5T3VLRnRRQXpwamJGTnhLWkFjeDRTdU9NOXRlRWtEX2tJQjY4TzZOdFdoc09DWHZ2Rk50QUxVaVFxVUd0SHZFZ0VtTmh4bm5iRTQ2dDVGNTdIdzBXTjRkdzM5dmU1REZRdk1UdEJ4TXIxVjdONnFiWldnbm1JTzhTRkk1SzVOMmxGRV82anRXLXZ0R21pWlp4cW1vWUpGa3B6aDR6enB2dGVJMHEtODlVWGVzVXpHV0pfNGlvRkpEeEhlMTdxUHRITVI0cktYT0pFRXR2QnBJMnBGQm5j0gHwAUFVX3lxTFBuT2hCUEptazdRd0xHY0FsT2x0SWQzSjVabjM0NC1LMnFYVVBYeFd1X1FSRUx1dTZtRWVJa0RWa3pUQWNST2J0NkxFOEktaURhOG85X3ZORG9kN1FmVW84YTdkaDdGR0JndlFIVFB2STZVU1k1TE1EdlJjYlN4YjFlbV9HaXRpUmpjVGl1bV9fMDMybVRoMlAxTkZ6VjFoa1hydkRCZVVPUDQ1NjE3SWlTZ0V2X0o0Ymx5cFZlbHZEQTdTVk5qUTVyM2ZBa2pvUnVIc2h3RVRBaG9wRFNsQ2hRbWJnV3NEZjRoWHAyWGpaNA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer drug VEPPANU shifts to Rigel in $85M Arvinas-Pfizer deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcEZEeEw3bF9WMjhZRWZlWGVFMHFVWEtSSGcyUm9GaTQ2SmZMWkwtU2pDWDBzRVdWbVE2QVF5NTZFdFVBN3ZReTBPZ2szRmhFWThDcmR0RHNoQzE1U0Rwc3JfSkxkWTctcU9UR3JHeHJwc2dDamxUeVVzZ0w2S1o4bVd0dTAxZVBzQ05UTm9vWUxoSFc0UlpFMFRvVjJsMHNXbTdoeTNQZkdYRXlJWnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rigel Pharmaceuticals (RIGL) Q1 EPS Compression Tests Bullish High\u2011Earnings Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOWTU5THhHQ1Mzc2NadzdQU2RGY0Q5alpzdUhDM3ZuVkltVWdORGFQZXdNR1VCWHR1QzlzNmdhcXNqR0d2Z2hYb3ltMEg3R0ZpdURnaXR6b1pRNGU3VF9ZYmk5SDhqSVl6RjNTLVJNQ1dIenk5VU9mTU9JVmpqTXJZeXlWQlVEajJFNld1Qi0xRm0tQjNZNVFyZks5Ni0zRHpHUk52dzQyOVg5LVc2V2g4dU9raWZlS0p4ZlpKYlg3N0l2QmMzOWpTZ2RESzNBZ2tjR2RVdC1VZm1oc1hZMXg0RFJ5VWpzZw?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Provides Business Update and 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQZ05PSVQ3Nl9EVmozX0JKcnJXY3FCbmJBUmRuYzhyLW9aMEZMZ3RpNHdiNTJva0xmVEpCcW1Ucmd3UkFwcnl6clNudDNEaFA3RHN5bmZOMk1NSDZYeTFIbVg3SWttTWlOaFNGZ2E4RnZYX3dzbW50a0VRV0twU19wc3BSbmFCYjMwTG9JeXVNajFQYzliOXlWSFBYNzZseUY2WUpxbjJn?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals CEO Raul Rodriguez on profitability and product growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNd0EtbjBHUWFNUGlOTzEtdXpiaU85Qnp2TUgxa3piNXZyOTc3OTdrMVZDbERGelIwUFJhRDFjdmJVSVAxY2FfYnhYenA3U0c0b1IzOXdwci1UTWpfQXVrZTIweHowYVEzak1QdE1WR1hCZ3BrWWtOSnRPdVRpN0ZjMVFpZ0VFYklUNld3QVU5X25Hd1NoUW9QMTJxWU5DNmpTeVlpS2NlQUpZZXJLZzZQV0RBYnhKaVdVU3dv?oc=5", "source_name": "CNBC", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOemZXOUdmbjBTSElVX3dRYTlGckNCelc3VFhSY0gwOTVmbGlZeU9wb1BaaXRHRDNoSlNxdVNZXzV5Z0dxX1hBdUpXdGV2cG1paTFsOFB4RTEyelJ1SUoxVGVRQjlZOGFfYzNLQ2FOYkgybWdKcElRWmdHM1l1QWNpbk5yYUJIblBEdmdRY1c2N0ZtMFBTWTFaOG9iN0VYUXVUMVZURHduRXJjV2xOVVI5Nng4MmpfOWN1amt5WFBpb0RNOXI4Mkg4bw?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-06T07:58:22+00:00", "published_display": "06 Aug 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57", "summary": "H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US), maintaining a target price of $57. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/74156453/hc-wainwright-maintains-rigel-pharmaceuticals-riglus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-08-06T08:41:24", "published_display": "06 Aug 2026 08:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts", "summary": "Rigel Pharmaceuticals (RIGL) saw its stock rally after its Q2 earnings release, with a 4.6% increase following a strong three-month run. The company maintained profitability with $17.3m in net income and $78.7m in total revenue, though revenue and EPS declined significantly year-", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rigl/rigel-pharmaceuticals/news/rigel-pharmaceuticals-rigl-stock-rally-runs-into-earnings-qu/amp", "source_name": "Simply Wall Street", "published_at": "2026-08-06T08:41:24", "published_display": "06 Aug 2026 08:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPanQ1a3hmdEs0Q3JoOTZUT3NsUEVLWHY5QjZhZUdPZkNVWEN5Qy1LUnJCby1PR2ZDRWVWOVRob1ZlZy1QVGhMWi1TRmdldFQxOFlCTV9ucHNKWnVEd1ZteDBEUlA0R191dkVlcFlXRm1WT21EN3RqWmhIc2VCYV9RNm5lMW1lbVZpcnZDUVlpQ29iUl8yX1JmaXhMR2FuVm1ON25wRWZ2dUh0T2c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-08-06T02:10:28+00:00", "published_display": "06 Aug 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNLVhkcWQzM0puSUx1ZS1qcWxwOE9RcUx5a1dRb3lQcXFpNG8ydEs4b2J2b2o3Q3hvT0tvczFOQU1OTlFYb0I4QXdTNFlnekJ5eXd5cnF4RjFIaTBCYWRzVjZ2VWNJcW9uR3A1eWxQNHI1MDBidUY3bnpJaVUwS2hfcEFTM0QzVVlQZnFEWEFzLUQtY1VDejJhNzB4ZWNKdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-08-05T18:29:23+00:00", "published_display": "05 Aug 2026 18:29", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/27667a71-d85c-3d85-88ee-3565f4d6ad27/rigel-pharmaceuticals%2C-inc..html", "source_name": "Moby", "published_at": "2026-08-05T12:30:00+00:00", "published_display": "05 Aug 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. (RIGL) Latest Stock News & Headlines", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE9FLXV4eHRya1ZjQjRRc1JSdHRDbmotQWRIQ3p1b194TFNsNGF4bmFVQklQdjR4WGdoOUl2QUJFZ3JkNFRXTjVBRFVfUTZfQmRUZGxUVi1rWXg?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-08-05T04:51:34+00:00", "published_display": "05 Aug 2026 04:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals (RIGL) Overvalued After Q2 Earnings Bea", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOMUk5N194LXZPQXEwR2dta2RFZlV5azdrYWJ1LTZWWVBUd0xGQ0ZkTlJ2VVpsSWVQcFlyZ2xRTjdCTmNDbjZUdV9rS0JsVUNYc0VPSHFOUlR6YWg2Z0d5LWU2Q2Q1ZEtuOS1oc0lYUXFSYjl6S2gwWmZUU3BNdGNMaGpvbHVtSU11MGZEaFFzZnFKUDhWY3pWQVplRE9xRmFGUWVpZXRfOGhtX1VISVRJZlMxOHNrUDdveWNaNXZxcHdPeEhXbFhfZUtEbS1vRlRKNlVHQzlNM0lkRWIxVVpaSUpVcnBYQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-08-05T03:12:31+00:00", "published_display": "05 Aug 2026 03:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Q2 2026 Earnings Call Transcript", "summary": "Rigel Pharmaceuticals reported strong Q2 2026 results, with commercial revenue growing 14% year-over-year, driven by record TAVALISSE sales and REZLIDHIA growth. The company is accelerating the launch of VEPPANU, an FDA-approved breast cancer therapy, which it expects to be its l", "url": "https://www.marketbeat.com/earnings/reports/2026-8-4-rigel-pharmaceuticals-inc-stock/", "source_name": "MarketBeat", "published_at": "2026-08-05T03:11:56", "published_display": "05 Aug 2026 03:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Q2 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/601d4af5-8d35-3458-a9aa-2c976afe24d8/rigel-pharmaceuticals-q2.html", "source_name": "MarketBeat", "published_at": "2026-08-05T02:03:51+00:00", "published_display": "05 Aug 2026 02:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RIGL)", "summary": "Rigel Pharmaceuticals, Inc. (RIGL) published a slide deck in conjunction with their Q2 2026 earnings call. The company reported an EPS of $0.88, beating estimates by $0.96, and revenue of $78.70M, which also beat estimates by $23.43M despite a 22.60% year-over-year decrease. This", "url": "https://seekingalpha.com/article/4930435-rigel-pharmaceuticals-inc-2026-q2-results-earnings-call-presentation", "source_name": "Seeking Alpha", "published_at": "2026-08-05T02:43:19", "published_display": "05 Aug 2026 02:43", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates", "summary": "Rigel Pharmaceuticals (RIGL) reported Q2 earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share, and significantly down from $3.28 per share a year ago. Despite missing EPS estimates, the company's Q2 revenues of $78.7 million surpassed the consensus", "url": "https://finance.yahoo.com/healthcare/articles/rigel-pharmaceuticals-rigl-q2-earnings-211503917.html", "source_name": "Market source", "published_at": "2026-08-04T21:11:56", "published_display": "04 Aug 2026 21:11", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel: Q2 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rigel-q2-earnings-snapshot-200854036.html", "source_name": "Associated Press", "published_at": "2026-08-04T20:08:54+00:00", "published_display": "04 Aug 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Reports Second Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQWnYtcHFHQnVoTXFmUHp5OUtqbW9FUU5hY3dNZXZHa3p4VWxjNWRONlVtcEkwSS1xS2E1cFN3LXp3OUEtT1lDaVl6eC1SSFV6ckUzVWV5Qzl5eU9uRWJkSkZqdWgzdVZsR0Fic3ZjZjZPQ1FTSXBXTjUyMFJIZjZIaEpBMzdib0ZjbFZUOXpvNDBmR1lNU3JZeC04MlhpUGo4TlA2WFBQYWFwTWlSSlZURjhn?oc=5", "source_name": "TradingView", "published_at": "2026-08-04T20:01:00+00:00", "published_display": "04 Aug 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(RIGL) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models, highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies an exceptional short setup with a significant risk-reward ratio and outlines specific trading strategies f", "url": "https://news.stocktradersdaily.com/news_release/34/RIGL_as_a_Liquidity_Pulse_for_Institutional_Tactics_080426064202_1785883322.html", "source_name": "Stock Traders Daily", "published_at": "2026-08-04T19:11:56", "published_display": "04 Aug 2026 19:11", "sentiment": "negative", "sentiment_pct": 27, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Rigel Pharmaceuticals Inc (RIGL), noting its current risk score of 4.47 and ranking it 86th out of 155 in the Pharmaceuticals industry. It highlights the company's beta of 1.19, indicating higher volatility compared to the S&P 500 index", "url": "https://www.tradingkey.com/markets/stocks/rigl/risk-assesment", "source_name": "TradingKey", "published_at": "2026-07-30T05:39:37", "published_display": "30 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results", "summary": "Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to di", "url": "https://www.tradingview.com/news/prnewswire:e86e3e35e2be2:0-rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financial-results/", "source_name": "TradingView", "published_at": "2026-07-29T05:10:49", "published_display": "29 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Rigel Pharmaceuticals Inc (RIGL), highlighting its current valuation score and P/E ratio. It notes that the company's P/E ratio is 1.90, significantly below its recent high and above its recent low. The analysis also indicates that re", "url": "https://www.tradingkey.com/markets/stocks/rigl/company-valuation", "source_name": "TradingKey", "published_at": "2026-07-29T03:41:07", "published_display": "29 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel schedules a live webcast for its Aug. 4 business update", "summary": "Rigel Pharmaceuticals (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. A live conference call and webcast will follow at 4:30 p.m. ET, led by senior management, to discuss the results and provide a b", "url": "https://www.stocktitan.net/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-kmaj6q3vc7qu.html", "source_name": "Stock Titan", "published_at": "2026-07-28T12:11:44", "published_display": "28 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGL|Rigel Pharmaceuticals Inc|Price:37.126|Chg%:-0.264", "summary": "This article provides a comprehensive stock analysis of Rigel Pharmaceuticals Inc (RIGL) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways recently. The analysis also covers the company's valuation, instit", "url": "https://www.tradingkey.com/markets/stocks/rigl/stock-analysis", "source_name": "TradingKey", "published_at": "2026-07-28T03:39:19", "published_display": "28 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Rigel Pharmaceuticals Inc (RIGL), highlighting major institutional investors and their holdings. It breaks down shareholders by type and reports on changes in institutional ownership over several quarters. The data provides insigh", "url": "https://www.tradingkey.com/markets/stocks/rigl/ownership", "source_name": "TradingKey", "published_at": "2026-07-27T19:11:44", "published_display": "27 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Revenue Breakdown \u2013 NASDAQ:RIGL", "summary": "Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) generated $294.28 million in revenue last year, primarily from its Novel Therapies segment. This is an increase from $179.28 million the previous year. The United States was the company's largest contributor to revenue.", "url": "https://www.tradingview.com/symbols/NASDAQ-RIGL/financials-segments/", "source_name": "TradingView", "published_at": "2026-07-27T15:11:44", "published_display": "27 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Rigel Pharmaceuticals Inc (RIGL). It indicates that the company has not distributed any dividends in the past five years. The report also details multiple merger-related stock splits with a 10:1 ratio that oc", "url": "https://www.tradingkey.com/markets/stocks/rigl/dividend-splits", "source_name": "TradingKey", "published_at": "2026-07-27T02:09:49", "published_display": "27 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Income Statement", "summary": "This article provides the quarterly and annual income statements for Rigel Pharmaceuticals Inc (RIGL), offering detailed financial data such as total revenue, cost of revenue, operating expenses, and net income across multiple fiscal years and quarters. It also includes frequentl", "url": "https://www.tradingkey.com/markets/stocks/rigl/income-statement", "source_name": "TradingKey", "published_at": "2026-07-26T04:20:13", "published_display": "26 Jul 2026 04:20", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Revenue Breakdown \u2013 MUN:RI2", "summary": "Rigel Pharmaceuticals, Inc. (MUN:RI2) generated 250.56 million EUR last year, a significant increase from 173.18 million EUR in the previous year. This revenue primarily stemmed from its Novel Therapies segment, with the United States being the largest contributing region. The co", "url": "https://www.tradingview.com/symbols/MUN-RI2/financials-segments/", "source_name": "TradingView", "published_at": "2026-07-25T08:12:42", "published_display": "25 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Rigel Pharmaceuticals Inc (RIGL) has a robust financial health score of 8.03, ranking 86th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a 10.28% year-over-year revenue increase to $58.82 million and a 24.39% year-over-year", "url": "https://www.tradingkey.com/markets/stocks/rigl/financial-health", "source_name": "TradingKey", "published_at": "2026-07-24T14:40:15", "published_display": "24 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RIGEL PHARMACEUTICALS INC (RIGL) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5vUnBwNzkyVHBZUDJpNXZtcmdBSEZVQklJNUQ5NzlaWEUwQkg5SDJkQ2FRcElINjhBRjlCU2REWDRsX0s4SWF2R3g4ODNLdjNGTTRYZ3hZcUh1MUExNVpHR0JHXzA?oc=5", "source_name": "ChartMill", "published_at": "2026-07-23T17:27:27+00:00", "published_display": "23 Jul 2026 17:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(RIGL) Risk Channels and Responsive Allocation", "summary": "Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is presenting a weak near-term sentiment, although an exceptional 81.5:1 risk-reward setup is noted, targeting a 24.2% gain against 0.3% risk. AI models have developed three trading strategies: Position Trading (LONG), Momentum Breakout (", "url": "https://news.stocktradersdaily.com/news_release/39/RIGL_Risk_Channels_and_Responsive_Allocation_072326025401_1784832841.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-23T14:27:19", "published_display": "23 Jul 2026 14:27", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Q1 2026 earnings summary", "summary": "Rigel Pharmaceuticals (RIGL) announced total revenues of $58.8 million in Q1 2026, including $54.9 million in net product sales, marking a 26% year-over-year increase. The company maintained profitability with an $8.7 million net income despite higher R&D and SG&A expenses, drive", "url": "https://quartr.com/events/rigel-pharmaceuticals-inc-rigl-q1-2026_onMowkE1", "source_name": "Quartr", "published_at": "2026-07-11T11:10:56", "published_display": "11 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Corporate presentation Summary", "summary": "Rigel Pharmaceuticals' corporate presentation outlines its transformational growth strategy, focusing on expanding its commercial business, advancing its pipeline, and in-licensing. The company has grown from one commercial product in 2020 to three by 2025, with a fourth, VEPPANU", "url": "https://quartr.com/events/rigel-pharmaceuticals-inc-rigl-corporate-presentation_onMowpQs", "source_name": "Quartr", "published_at": "2026-07-11T11:10:56", "published_display": "11 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing by Rigel Pharmaceuticals Inc. for transactions that occurred on July 10th. The filing is a standard regulatory disclosure related to insider trading, though the article does not provide specific details from the form itself. The document si", "url": "https://ng.investing.com/news/stock-market-news/form-4-rigel-pharmaceuticals-inc-for-10-july-93CH-2595754", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T01:41:22", "published_display": "11 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) CMO receives 24,400-share RSU equity award with 4-year vesting", "summary": "Rigel Pharmaceuticals' EVP and Chief Medical Officer, Alison L. Hannah, was granted 24,400 Restricted Stock Units (RSUs) which will vest annually over four years, starting July 8, 2027. Following this award and the cancellation of 5,750 RSUs, Ms. Hannah directly holds 35,025 shar", "url": "https://www.stocktitan.net/sec-filings/RIGL/form-4-rigel-pharmaceuticals-inc-insider-trading-activity-8d44c3c9628b.html", "source_name": "Stock Titan", "published_at": "2026-07-11T01:40:25", "published_display": "11 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Proxy filing Summary", "summary": "Rigel Pharmaceuticals has issued a proxy filing summarized on April 3, 2026, outlining key proposals for its annual meeting scheduled for May 14, 2026. Shareholders will vote on the election of three directors, amendments to two equity incentive plans to add shares, an advisory v", "url": "https://quartr.com/events/rigel-pharmaceuticals-inc-rigl-proxy-filing_onMowMMR", "source_name": "Quartr", "published_at": "2026-07-08T08:39:51", "published_display": "08 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Announces Inducem", "summary": "NULL", "url": "https://www.moomoo.com/news/flash/22754760/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule", "source_name": "Moomoo", "published_at": "2026-07-07T20:11:01", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQUWJEdU5GS0FXZ1ZlYmRPd0cyVHZ1bEYwZHNEekVPRTAtaTJjYVVKbndNSnJGRFloUFFwU2ZlWk5GQ2pySjNNS2w5UXN6OW1YVFlGeWx3Y1ByWFVwNHFVeVlkZnE0TGZraUFHNm9EQkFQcGZaSS1FZWpNUXpSd2FLeGpsdm05ZGlzUE5lRjVZZFRhSGRzREZ1dXhQSkpHa2lBSnpDTTcyV0ZXSUN0eC1weUZYVjd0SzZsV0VSdGNhSDlYTnZyRTNrclVjbmtaSFpTTmVRYS12RlZZUQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (RIGL) director sells 2,500 shares under 10b5-1 plan for tax withholding", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNeWVjYnlwbVR4ZlAzTGpyOFNPWlhLUWFFVGtrOVZyX0FqOEJIRndMY0I4VlhNT2pqeDZpLTlPRjJZdlVWOG1WNXlwRkM0WExMbVl3QjhPTE52YW8wRkZLWUtOamhaMklla1RxdXliU2xvU19iQWRJcmlTSmxQU1NkMDBTSk5WaXQ3TVVSekVNdE14bDJVZUlLTHRwTjV3VUhFTDZNVWV4TkhOc3FMZ1JSbmRLRmFiMnZobmUw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) CEO gets 31,700 performance-based options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMEd2eXAtUFZUcHpQZFpZYnlOMDh5NUhBVWxVcjNtOE0wWFl1ZzJ3SV9IR04xeThCV1NETUNPa1VtWU1NclNUMGtBNWlMLVFYNDZ6N1RZa1djOTYwTWw4QzN1UHFKRHBxd1RsX1VPNnR3TjJKOGpwUE5FV3N4YzA4T2UyREVwY2FKV2lFN3dFbnV0YXUySk5WXzRxaF9iR3dvZ0ZtcFJ6NXM5SWFhMmhOSFZkdzdjYlYxVlFj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel (RIGL) CFO\u2019s 7,394-share performance-based stock option fully vests", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOTA4aWpsYk9CMGFLYnBmbF8tLXNSNmotRW9qS3h2QmFfSGhwZExIblV5Z0hpeWxOcUdDNXNZZ0dsOU15dXdDa2I1RWpDbndYeTFtQy1zTXdNY3VZcXFjQzB4TWpjcEdYT2loZlBfRElEaW5Cd2NrNGQ2bDM0QWUyLUtpd0hKYW5PdjVvLWpERFl3SGRLRFVNLXZ3Z1NDenVqeC0waEVfM0xwYzBkbTBTX0tlS2p2YTBERlpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQaUl0VEFNeThOTThJcVFkTXM3VW9TYzVnNTVDakwxcTN2N0Z0aTl3clZqd1VYVlJfbmdTTjlBcjFJRkpRbElSdXhnWUtPZ3JrTGZ1UTBPM2ozOVdyMU9UanpMU1ZIOWRoa1VObnYtT0tZMjRGTkJIMGdGZzZ0NnVKekRrMFlZbi1LeGpxTWFSRF8zNDlHMEI0S2JB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA\u2011Approved Breast Cancer Drug VEPPANU", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Believe Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are A Poor Guide For Its Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSlg0NUxGb0FWRGZDd1lWWVBfVTI2dGpodU1aWElzQmtoaDBZaGduV2kxcEhuU0lxNHRSNjk0M3hhYWxiM2FRSjd1dGlGaHhoRUw0TVJRS1I5MTBNdGJCSVdvV3RycWFoTDlDZDFzdUJJbnVsWkJuWHhxWldlQno1QlpiZXZGU0Qtc3VDTXBMQkduRGNFTk4tVzBzRVpnalRJeFNzQkg1QXREQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer drug VEPPANU shifts to Rigel in $85M Arvinas-Pfizer deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcEZEeEw3bF9WMjhZRWZlWGVFMHFVWEtSSGcyUm9GaTQ2SmZMWkwtU2pDWDBzRVdWbVE2QVF5NTZFdFVBN3ZReTBPZ2szRmhFWThDcmR0RHNoQzE1U0Rwc3JfSkxkWTctcU9UR3JHeHJwc2dDamxUeVVzZ0w2S1o4bVd0dTAxZVBzQ05UTm9vWUxoSFc0UlpFMFRvVjJsMHNXbTdoeTNQZkdYRXlJWnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals (RIGL) Q1 EPS Compression Tests Bullish High\u2011Earnings Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOWTU5THhHQ1Mzc2NadzdQU2RGY0Q5alpzdUhDM3ZuVkltVWdORGFQZXdNR1VCWHR1QzlzNmdhcXNqR0d2Z2hYb3ltMEg3R0ZpdURnaXR6b1pRNGU3VF9ZYmk5SDhqSVl6RjNTLVJNQ1dIenk5VU9mTU9JVmpqTXJZeXlWQlVEajJFNld1Qi0xRm0tQjNZNVFyZks5Ni0zRHpHUk52dzQyOVg5LVc2V2g4dU9raWZlS0p4ZlpKYlg3N0l2QmMzOWpTZ2RESzNBZ2tjR2RVdC1VZm1oc1hZMXg0RFJ5VWpzZw?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Provides Business Update and 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQZ05PSVQ3Nl9EVmozX0JKcnJXY3FCbmJBUmRuYzhyLW9aMEZMZ3RpNHdiNTJva0xmVEpCcW1Ucmd3UkFwcnl6clNudDNEaFA3RHN5bmZOMk1NSDZYeTFIbVg3SWttTWlOaFNGZ2E4RnZYX3dzbW50a0VRV0twU19wc3BSbmFCYjMwTG9JeXVNajFQYzliOXlWSFBYNzZseUY2WUpxbjJn?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals CEO Raul Rodriguez on profitability and product growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNd0EtbjBHUWFNUGlOTzEtdXpiaU85Qnp2TUgxa3piNXZyOTc3OTdrMVZDbERGelIwUFJhRDFjdmJVSVAxY2FfYnhYenA3U0c0b1IzOXdwci1UTWpfQXVrZTIweHowYVEzak1QdE1WR1hCZ3BrWWtOSnRPdVRpN0ZjMVFpZ0VFYklUNld3QVU5X25Hd1NoUW9QMTJxWU5DNmpTeVlpS2NlQUpZZXJLZzZQV0RBYnhKaVdVU3dv?oc=5", "source_name": "CNBC", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxPTFlzc3AzYmlzdG0zQXQ4eEd2TDJlT0h5bGlMVUdRd0JjLWd2Qm5kVU5oR3VWX19BVENjbXlqcVM3NFMwT0FDTHQwY05WNk96aGhpM3pQMWZWcExyeGVZaXFkeDVtMTlwVnM5RlNaTTNHYVhVYkFDQ3kwczlFeTlUN1huR1FJbHdBT2ZTajJ6VEFPVFI0MkZoMzRIMjc2Y182WEJpREFjZno4VzRDZF85R1lrdjNhVi1pYm01RHJDRTJmWHF0OHpMOXFyLTJuLWgydEFBX3JGTGtBSzlVSmdER2NnVUdJbERJVkRxOGo1MFlHMHZXMUxZU0hFOWxIdw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-12T07:00:00+00:00", "published_display": "12 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 59, "sentiment_summary": {"positive": 12, "negative": 6, "neutral": 41, "score": 52, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 15.41, "count": 29}, {"event": "general", "label": "Market update", "weight": 13.15, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 1.45, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 36.81, "latest_week": "2026-07-31", "one_week_move": 0.2, "four_week_move": -4.9, "twelve_week_move": 41.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.889838, "market_dynamics_buy_signal": false, "relative_strength": -4.058824, "fair_value_gap": 70.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.5341, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.2% over one week, -4.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 49, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 8}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "Seeking Alpha", "count": 4}, {"label": "MarketBeat", "count": 3}, {"label": "Quartr", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 29}, {"label": "Market update", "count": 22}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.2% over one week, -4.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL"}], "updated_at": "2026-08-08T07:49:26.596003+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}